Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May;25(3):271-280.
doi: 10.1097/MCP.0000000000000570.

New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease

Simon F K Lee  1 , Barbara E Laughon  2 , Timothy D McHugh  3 , Marc Lipman  4
Affiliations
Review

New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease

Simon F K Lee et al. Curr Opin Pulm Med. 2019 May.

Abstract

Purpose of review: Treatment of drug-sensitive tuberculosis (TB) is effective, whereas that of multidrug-resistant and extensively drug-resistant TB as well as nontuberculous mycobacterial (NTM) disease are less so. Therapy in general requires good adherence to potentially toxic drug regimens over prolonged periods. Poor adherence is associated with resistance development and poor outcome. This review will present promising new treatments, both new drugs and regimens, for difficult mycobacterial pulmonary infections.

Recent findings: A number of new and repurposed drugs including bedaquiline, delamanid, pretomanid, linezolid and clofazimine, and drug regimens, such as the The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB (STREAM) trial regimens, are currently progressing from basic research through clinical trials.

PubMed Disclaimer

MeSH terms